FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589341756> ?p ?o ?g. }

• W2589341756 abstract "Abstract XBP1 (X-box binding protein 1), CD138 (Syndecan-1), and CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) are highly expressed antigens associated with tumor pathogenesis in multiple myeloma cells and various solid tumor cells. We have previously reported on the use of HLA-A2 peptides specific to these antigens to generate antigen-specific and HLA-2-restricted cytotoxic T cells (CTL) in preclinical studies and phase I/II clinical trials in patients with smoldering MM. These studies extend this concept to HLA-A24 patients. Immunogenic HLA-A24 peptides specific to both the spliced and unspliced isoforms of XBP1, CD138, and CS1 were identified, synthesized, and evaluated in vitro for their ability to generate the antigen-specific cytotoxic T lymphocytes (CTL) targeting tumor cells. The specific epitopes were selected based on their binding affinity to HLA-A24, extended half-time disassociation rates, proteasomal C terminal cleavage, and TAP transport. We report here on novel highly immunogenic HLA-A24-specific peptides XBP1 US185 -193 (I S P W I L A V L), XBP1 SP223-231 (V Y P E G P S S L), CD138265-273 (I F A V C L V G F), and CS1240-248 (L F V L G L F L W), which induce antigen-specific CD3+CD8+ CTL against MM and various solid tumors. Each of the single peptide-specific CTL displayed immune functional activities including IFN-g/IL-2 cytokine production and cytotoxic activity against HLA-A24+ MM cells. Furthermore, our studies demonstrated that a cocktail of the four HLA-A24-specific peptides induced multipeptide-specific CD3+CD8+ CTL with functional anti-tumor properties against myeloma cells. Phenotypically, the multipeptide-specific CTL were central memory (CM; CCR7+CD45RO+/CD3+CD8+), effector memory (EM; CCR7-CD45RO+/CD3+CD8+) and terminal effector (TE; CCR7-CD45RO-/CD3+CD8+) cells expressing high levels of cell activation markers CD69, CD38, and CD40L. The multipeptide-specific effector and memory CTL subsets demonstrated HLA-A24-restricted and peptide-specific anti-tumor activities, and the highest activities were detected within the CM CTL subset. Treatment of the multipeptide-specific CTL or tumor target cells with different types of checkpoint inhibitors (a-PD1, a-TIM3, a-PDL-1, a-Galectin-9) or the immune modulator drug, lenalidomide, enhanced their anti-myeloma activities and antigen-specific CD3+CD8+ T cell proliferation to HLA-A24+ tumor cells. Therefore, a cocktail of the four immunogenic HLA-A24 epitopes provides the framework for development of a cancer vaccine based targeted immunotherapy. In conclusion, we report here on novel immunogenic HLA-A24-specific XBP1 unspliced, XBP1 spliced, CD138, and CS1 peptides that elicit CTL with anti-myeloma activities. These peptides will allow us to extend our immunotherapeutic vaccine approach beyond the current HLA-A2-specific peptides to HLA-A24 patients with smoldering myeloma, multiple myeloma, other plasma cell disorders and potentially with solid tumors. These preclinical studies also demonstrate that incorporation of immunomodulatory agents and/or checkpoint inhibitors can amplify and maintain antigen-specific memory CTL responses against tumor. Disclosures Bae: OncoPep Inc.: Consultancy, Equity Ownership. Raje:Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Merck: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Research Funding; Eli Lilly: Research Funding. Richardson:Jazz Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees. Hideshima:C4 Therapeutics: Equity Ownership; Acetylon: Consultancy. Chauhan:Stemline Therapeutics: Consultancy. Munshi:OncoPep Inc.: Equity Ownership, Membership on an entity's Board of Directors or advisory committees. Anderson:Millennuim: Membership on an entity's Board of Directors or advisory committees; C4 Therapeutics: Equity Ownership; Acetylon: Equity Ownership; Oncoprep: Equity Ownership; Gilead: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Acetylon: Equity Ownership; Millennuim: Membership on an entity's Board of Directors or advisory committees; C4 Therapeutics: Equity Ownership; Celgene: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees; Oncoprep: Equity Ownership; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees." @default.
• W2589341756 created "2017-03-03" @default.
• W2589341756 creator A5000842104 @default.
• W2589341756 creator A5006765393 @default.
• W2589341756 creator A5032464400 @default.
• W2589341756 creator A5043322435 @default.
• W2589341756 creator A5043526996 @default.
• W2589341756 creator A5045740077 @default.
• W2589341756 creator A5061032029 @default.
• W2589341756 creator A5061963412 @default.
• W2589341756 creator A5075669283 @default.
• W2589341756 creator A5091207345 @default.
• W2589341756 date "2016-12-02" @default.
• W2589341756 modified "2023-09-27" @default.
• W2589341756 title "Identification and Validation of HLA-A24 XBP1us, XBP1sp, CD138, and CS1 Peptides to Generate Antigens Specific-Cytotoxic T Lymphocytes: Preclinical Basis for Vaccine Therapy in HLA-A24 Patients with Multiple Myeloma and Other Cancers" @default.
• W2589341756 doi "https://doi.org/10.1182/blood.v128.22.5689.5689" @default.
• W2589341756 hasPublicationYear "2016" @default.
• W2589341756 type Work @default.
• W2589341756 sameAs 2589341756 @default.
• W2589341756 citedByCount "0" @default.
• W2589341756 crossrefType "journal-article" @default.
• W2589341756 hasAuthorship W2589341756A5000842104 @default.
• W2589341756 hasAuthorship W2589341756A5006765393 @default.
• W2589341756 hasAuthorship W2589341756A5032464400 @default.
• W2589341756 hasAuthorship W2589341756A5043322435 @default.
• W2589341756 hasAuthorship W2589341756A5043526996 @default.
• W2589341756 hasAuthorship W2589341756A5045740077 @default.
• W2589341756 hasAuthorship W2589341756A5061032029 @default.
• W2589341756 hasAuthorship W2589341756A5061963412 @default.
• W2589341756 hasAuthorship W2589341756A5075669283 @default.
• W2589341756 hasAuthorship W2589341756A5091207345 @default.
• W2589341756 hasConcept C147483822 @default.
• W2589341756 hasConcept C147969180 @default.
• W2589341756 hasConcept C153911025 @default.
• W2589341756 hasConcept C154317977 @default.
• W2589341756 hasConcept C167672396 @default.
• W2589341756 hasConcept C185592680 @default.
• W2589341756 hasConcept C195616568 @default.
• W2589341756 hasConcept C202751555 @default.
• W2589341756 hasConcept C203014093 @default.
• W2589341756 hasConcept C2776662205 @default.
• W2589341756 hasConcept C502942594 @default.
• W2589341756 hasConcept C55493867 @default.
• W2589341756 hasConcept C86803240 @default.
• W2589341756 hasConceptScore W2589341756C147483822 @default.
• W2589341756 hasConceptScore W2589341756C147969180 @default.
• W2589341756 hasConceptScore W2589341756C153911025 @default.
• W2589341756 hasConceptScore W2589341756C154317977 @default.
• W2589341756 hasConceptScore W2589341756C167672396 @default.
• W2589341756 hasConceptScore W2589341756C185592680 @default.
• W2589341756 hasConceptScore W2589341756C195616568 @default.
• W2589341756 hasConceptScore W2589341756C202751555 @default.
• W2589341756 hasConceptScore W2589341756C203014093 @default.
• W2589341756 hasConceptScore W2589341756C2776662205 @default.
• W2589341756 hasConceptScore W2589341756C502942594 @default.
• W2589341756 hasConceptScore W2589341756C55493867 @default.
• W2589341756 hasConceptScore W2589341756C86803240 @default.
• W2589341756 hasLocation W25893417561 @default.
• W2589341756 hasOpenAccess W2589341756 @default.
• W2589341756 hasPrimaryLocation W25893417561 @default.
• W2589341756 hasRelatedWork W2551292439 @default.
• W2589341756 hasRelatedWork W2720199625 @default.
• W2589341756 hasRelatedWork W2783475124 @default.
• W2589341756 hasRelatedWork W2784315056 @default.
• W2589341756 hasRelatedWork W2784961926 @default.
• W2589341756 hasRelatedWork W2785223093 @default.
• W2589341756 hasRelatedWork W2903747108 @default.
• W2589341756 hasRelatedWork W2907214140 @default.
• W2589341756 hasRelatedWork W2908348111 @default.
• W2589341756 hasRelatedWork W2912543579 @default.
• W2589341756 hasRelatedWork W2979601799 @default.
• W2589341756 hasRelatedWork W2982779342 @default.
• W2589341756 hasRelatedWork W2984333209 @default.
• W2589341756 hasRelatedWork W2987673820 @default.
• W2589341756 hasRelatedWork W2988597280 @default.
• W2589341756 hasRelatedWork W2988614964 @default.
• W2589341756 hasRelatedWork W2989253463 @default.
• W2589341756 hasRelatedWork W2989694473 @default.
• W2589341756 hasRelatedWork W2990526267 @default.
• W2589341756 hasRelatedWork W2995331096 @default.
• W2589341756 isParatext "false" @default.
• W2589341756 isRetracted "false" @default.
• W2589341756 magId "2589341756" @default.
• W2589341756 workType "article" @default.